利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.023 秒)

    CONDENSED PYRIDINE COMPOUND
    2.
    发明公开
    CONDENSED PYRIDINE COMPOUND 审中-公开
    KONDENSIERTE PYRIDINVERBINDUNG

    公开(公告)号：EP2123651A1

    公开(公告)日：2009-11-25

    申请号：EP08703164.7

    申请日：2008-01-11

    申请人： Astellas Pharma Inc.

    发明人： SHIRAKAMI, Shohei ,  INOUE, Takayuki ,  MUKOYOSHI, Koichiro ,  NAKAJIMA, Yutaka ,  USUDA, Hiroyuki ,  HAMAGUCHI, Hisao ,  HIGASHI, Yasuyuki ,  HATANAKA, Keiko

    IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/55 ,  A61P29/00 ,  A61P37/00 ,  A61P37/02 ,  A61P43/00 ,  C07D471/14

    CPC分类号： C07D471/04 ,  C07D471/14

    摘要： The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases.
    As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention.
    More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).

    摘要翻译： 本发明提供具有优异的JAK3抑制活性的化合物，可用作治疗和/或预防各种免疫疾病，包括自身免疫性疾病，炎性疾病和过敏性疾病的药剂的活性成分。 作为关于新的稠合杂环衍生物的研究结果，本发明人证实了缩合吡啶化合物具有优异的JAK3抑制活性，从而完成了本发明。 更具体地说，由于本发明化合物对JAK3具有抑制活性，所以该化合物可用作治疗或预防由不良细胞因子信号转导引起的疾病（例如活体排斥）的药剂的有效成分 器官/组织移植，自身免疫性疾病，哮喘，特应性皮炎，风湿病，牛皮癣和动脉粥样硬化疾病）或由细胞因子信号转导异常引起的疾病（如癌症和白血病）。

    NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND
    5.
    发明公开
    NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND 有权
    NITROGENIERTE BICYCLISCHE AROMATISCHE HETEROCYCLISCHE VERBINDUNG

    公开(公告)号：EP2840083A1

    公开(公告)日：2015-02-25

    申请号：EP13777902.1

    申请日：2013-04-17

    申请人： Astellas Pharma Inc.

    发明人： NAKAJIMA, Yutaka ,  IMADA, Sunao ,  TAKASUNA, Yuji ,  AOYAMA, Naohiro ,  NIGAWARA, Takahiro ,  SHIRAKAMI, Shohei ,  SHIRAI, Fumiyuki ,  SATO, Junji ,  NAKANISHI, Keita ,  KUBO, Kaori

    IPC分类号： C07D487/04 ,  C07D473/00 ,  A61K31/519 ,  A61K31/5377 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00

    CPC分类号： A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  C07D473/00 ,  C07D487/04

    摘要： [Problem] On the basis of a cathepsin S inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided.
    [Means for Solution] It was found that a nitrogen-containing bicyclic heterocyclic compound has the excellent cathepsin S inhibitory effect, thereby completing the invention. The compound of the present invention has the cathepsin S inhibitory effect, and can be used as an agent for preventing and/or treating autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like.

    摘要翻译： [问题]基于组织蛋白酶S抑制效果，提供了用于治疗或预防自身免疫性疾病，过敏性疾病，器官，骨髓或组织的移植物排斥，系统性红斑狼疮等的优异的药剂。 [解决方案]发现含氮双环杂环化合物具有优异的组织蛋白酶S抑制作用，从而完成了本发明。 本发明的化合物具有组织蛋白酶S抑制作用，可用作预防和/或治疗自身免疫性疾病，过敏性疾病，器官移植排斥反应，骨髓或组织，系统性红斑狼疮等的药剂 。

    FUSED PYRROLOPYRIDINE DERIVATIVE
    6.
    发明公开
    FUSED PYRROLOPYRIDINE DERIVATIVE 审中-公开
    稠合吡咯并吡啶衍生物

    公开(公告)号：EP2420502A1

    公开(公告)日：2012-02-22

    申请号：EP10764459.3

    申请日：2010-04-13

    申请人： Astellas Pharma Inc.

    发明人： SHIRAKAMI, Shohei ,  NAKAJIMA, Yutaka ,  MAEDA, Jun ,  TOMINAGA, Hiroaki ,  YAMAGISHI, Hiroaki ,  HONDO, Takeshi ,  INAMI, Masamichi ,  MORIO, Hiroki ,  INOUE, Takayuki ,  MIZUTANI, Tsuyoshi ,  ISHIOKA, Hiroki

    IPC分类号： C07D471/14 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/541 ,  A61K31/55 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00

    CPC分类号： C07D471/14 ,  C07D519/00

    摘要： [Problem]
    The present invention provides a condensed pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases caused by undesirable cytokine signal transduction or diseases caused by abnormal cytokine signal transduction.
    [Means for Solution]
    The present inventors have extensively studied a compound having a JAK inhibitory action, and as a result, they have found that a condensed pyrrolopyridine derivative which is the compound of the present invention has an excellent JAK inhibitory action, and is therefore useful as an agent for preventing or treating diseases caused by undesirable cytokine signal transduction or diseases caused by abnormal cytokine signal transduction, thereby completing the present invention.

    摘要翻译： 本发明提供可用作药物组合物的有效成分的缩合吡咯并吡啶衍生物，特别是用于预防或治疗由不良细胞因子信号转导引起的疾病或由异常细胞因子信号转导引起的疾病的药物组合物。 [溶液的方法]本发明人对具有JAK抑制作用的化合物进行了广泛的研究，结果发现作为本发明化合物的稠合吡咯并吡啶衍生物具有优异的JAK抑制作用，因此， 可用作预防或治疗由不良细胞因子信号转导引起的疾病或异常细胞因子信号转导引起的疾病的药物，从而完成本发明。